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6 Fig. 1. Data alignment and methodology for classification. (a) Principal component (PC) 1 and PC2 of a PC analysis, in the gene expression (GE) data pre-adjustment for batch effects (raw) and post-adjustment (quantile normalization+COMBAT) (see Fig S1 for DNA methylation data (MET)). Colors represent the dataset sources (GDSC and CCLE are two sources for the cell lines, and TCGA is the source for the tumors). (b) ROC curves for classifying TCGA versus cell lines in the data pre-adjustment (orange) and post-adjustment (blue) for GE and MET. (c) An overview of the HyperTracker methodology applied in the manuscript. First, we systematically identified possible mislabeled cell lines using GE and MET data, independantly. Second, we used various types genomic data to corroborate the hits. Third, we further validate the cell lines suspected to originate from skin using independent data. had very high AUPRC scores: 0.98 and 0.97 for GE and MET respectively (average across cancer 168 types). This means that transcript level data and DNA methylation data are largely sufficient to 169 accurately distinguish those cancer types. 170 171 Next, we obtained predictions of cancer type identity for each cell line. For every cancer type, we 172 split TCGA data randomly into training and testing sets, and we used the calculated precision-173 recall curve of the testing data to obtain the False Discovery Rate (FDR) score for every cell line 174 (details in Methods; all FDR values are listed in Table S1 ). The smaller the FDR, the more likely 175 the cell line is to belong to that particular cancer type. As expected, most of the cancer type labels 176 of the cell lines match the declared tissue of origin of that cell line --they tend to cluster at low 177 FDR values for the cognate cancer type (red dots in Fig 2a, Fig S2) . However, among these many 178 correctly classified cell lines (red dots), there are some with similarly low FDR scores, but which 179 were originally annotated as belonging to another cancer type (Fig 2a; blue dots with label shown). 180
A clustering analysis of the GE and MET values for the genes that had the highest weight in the 181 classification models (Fig 2b, Fig S3) showed that in most cases, the samples clearly cluster by 182 cancer type, but not by CL versus TCGA label. Moreover, we observed that the suspected cell 183 lines (cell lines with highly confident FDR scores to a different cancer type) tend to cluster with 184 the newly-assigned cancer type by the classifier, rather than with the original one (Fig 2b) . 185
186
In further analyses, we designated as the 'golden set' those cell lines that have FDR <= 0.3 for 187 both GE and, independently, for MET in their originally declared cancer type (n=366 out of 614 188 examined cell lines, 60%). For these cell lines, two independent types of evidence --189 transcriptomes and epigenomes --support that they match their expected cancer type well, 190 suggesting these cell lines would be preferred as experimental models. Further, we designated 191 as the 'silver set' those cell those cell lines that have FDR <= 0.3 for only one classifier (either 192 GE or MET but not both) (n=131 out of 614 examined cell lines, 21%). From the remaining 117 193 cell lines, we selected as 'suspect set' those CL which exhibit an FDR <= 30% for both GE and 194 for MET, but in a different cancer type than declared for that cell line (n=43 out of 614, 7% of 195 analyzed cell lines) (Fig 1c) . This set of cell lines may consist either of mislabeled cell lines, where 196 the cancer type of origin is different than it was thought, or of heavily diverged cell lines, where 197 the genomic and/or epigenomic alterations accumulating during cell culture have overridden the 198 original cancer type identity. Of note, cell line cross-contamination issues (23) cannot underlie the 199 trends we observe, because the repositories that provided GE and MET data have used genetic 200
Fig. 2. Detection of cell lines mislabelled to a different cancer type. (a)
False Discovery Rate (FDR) scores for 614 cell lines were calculated in MET and GE cancer type classifiers (one-versus-rest). The lower the FDR, the higher the confidence that the sample belongs to that particular cancer type (here, to SKCM, KIRC and CRAD from left to right, see Fig S2 for the other cancer types). The cell lines that were originally annotated as the cancer type that is being tested are shown in red, the rest in blue. (b) Heatmap for the 25 genes (GE) and CpG probes (MET) whose Ridge regression coefficients had the highest absolute values for SKCM (skin cancer) versus rest classifiers. The suspected skin cell lines are labeled in the right side of the heatmap. The cancer types shown are the suspected one (SKCM in this case) and additionally the originally declared cancer types of the suspected cell lines (here, ESTAD, SARC, CRAD and GYNE). See Fig S3 for the Heatmaps for the rest of the suspected cell lines. (c) Overview of the results from the systematic mislabelling testing of all cell lines. Cell lines with an FDR<=0.3 to its original cancer type in (i) GE and MET are assigned to the 'golden set' group and (ii) either GE or MET are assigned to the 'silver set'. If however the FDR<=0.3 to a different cancer type in GE and in MET, the cell line is assigned to the suspected set. 9 markers to ascertain the identity of the cell lines (4). The fact that two classifiers based on 202 independent data types --one genomic and one epigenomic --reached the same predictions 203 adds confidence that these are bona fide cases of mistaken tissue/cell-type identity. We detected 43 cell lines that bear transcriptomic and also epigenomic features of a different 208 cancer type than the one they were originally annotated to. We next turned to support individual 209 examples of cell lines with reassigned tissue identity by analyzing independent data. In particular, 210 we used genomic sequence-based classifiers, which are able to predict the tissue of origin based 211 on mutation patterns (24,25). As in our recent work (24), we used the trinucleotide mutation 212 spectra and the oncogenic mutations. In this validation setting, we applied such genomic 213 classifiers to a problem of 'one-versus-one' classification, where we contrasted the originally 214 assigned cancer type versus the newly-proposed cancer type for each reassignment. We found 215 that such one-versus-one classifiers based on genomic data had satisfactory accuracy with our 216 whole-exome sequencing data sets ( Fig S4; our past work (24) suggests whole genome 217 sequences are more powerful). Finally, we included an additional classifier based on copy number 218 alteration (CNA) profiles, which were also shown to yield accurate predictive models of tissue 219 specificity (24,25). 220
221
For the 43 examples of suspected cell lines tissue identity, we first derived one-versus-one 222 classification models separately for GE and MET. If a cell line is truly mislabelled when testing 223 the original versus the suspected cancer type, we should observe the same reassignment of the 224 cell line to be robustly observed across multiple runs of the classification algorithm, which use 225 different random initializations. Out of 20 iterations of the algorithm, a score of 20 indicates that 226 the cell line is consistently predicted as the suspected cancer type, and a score of 0 means that 227 the cell line is consistently assigned to the original cancer type. We randomized the labels to 228 obtain a background model of expected values (Fig 3b; Fig S5a) . From the 43 suspected cell 229 lines, 35 are consistently reassigned to the other tissue (score>10), irrespective of the variability 230 in the predictive models introduced by resampling the data (Fig 3a; Fig S5b) . Next, we calculated 231 the same score for the genomic classifiers (based on mutations and CNA, as described above) 232 on these 35 suspected cell lines (Fig 3a) . 233 234 by one or more genomic classifiers (Fig 3a; score>=15, corresponding to FDRs of 0%, 0% and 236 18% for the CNA, OGM and MS96 respectively, based on randomized data; Fig 3b) . This data 237 suggests 22 cell lines are candidates for assignment to another cancer type, based on converging 238 evidence from the levels of the genome, epigenome and transcriptome, which provides 239 confidence. Reassuringly, this list contains two cell lines which have been previously shown to be 240 misclassified: SW626 which was initially annotated as ovarian cancer but later discovered to be 241 derived from colon cancer (26), and COLO741 which was originally thought to be a colon 242 adenocarcinoma cell line but later shown to originate from a melanoma (27). The fact that these 243
two known examples were detected and reassigned to the correct cancer type provides evidence 244 that our method is overall reliable. 245
246
The two plausible reasons why a cell line thought to originate from one cell type would need to be 247 reassigned to a different cell type are (i) that at the time of isolation, the cell line was not of the 248 type that it was thought to be (mislabeling), or (ii) that during prolonged cell culture, the cell line 249 diverged greatly and now resembles another cell type (transdifferentiation). Our data allows to 250 examine how prevalent each case is: mislabelling is expected to be reflected equally in both the 251 epigenome and the genome, while transdifferentiation is expected to be reflected more strongly 252 in the (presumably more malleable) epigenome, and less so in the genome, which retains the 253 mutations from the original tumor. We suggest that mislabelling at isolation is a much more 254 common scenario ( 
Validation of cell lines suspected to originate from the skin 261
From the previous analysis, we identified a total of six cell lines which are reassigned from various 262 cancer types to skin cancer. We note that, of skin cancers, the TCGA study contains only 263 melanoma but not the non-melanoma skin cancers, so we are currently not able to distinguish 264 between cell type identities of different types of skin cancer. 265 266 11
To further support that these cells are indeed skin cancer cells, we performed an independent 267 analysis based on mutational signatures to confirm the mislabelling. Large-scale analyses of 268 trinucleotide mutation spectra across human tumors have revealed at least 30 different types of 269 mutational signatures (28). Of these, Signature 7 (C>T changes in CC and TC contexts) was 270 associated with exposure to UV light and is highly abundant in sun-exposed melanoma tumors 271 (29). The same signatures were recently estimated in cancer cell lines by two related methods 272 (30,31), which enabled us to use existence UV-linked Signature 7 to examine whether these cell 273 lines originated from the skin. Based on mutational burden of Signature 7, the known melanoma 274 cell lines (turquoise dots) are clearly separated from the rest (Fig 3e) , meaning the approach can 275 distinguish skin-derived cells. Among the melanoma cell lines with high mutational burden of 276 Signature 7, we found four out of five of the suspected cell lines (Fig 3e) , in particular GCT, 277 SW684, ES2 and MDST8 are very likely skin cells, and not sarcoma, sarcoma, ovarian cancer or 278 colorectal cancer, respectively, as originally thought. For the sixth suspected cell line COLO741, 279 the mutational signature data is not available, however COLO741 has been previously reported 280 of being melanoma based on the expression of skin-specific genes (27). 281
282
The RF48 cell line (originally considered stomach, here putatively reassigned to skin) does not 283 exhibit the UV signature nor the DNA methylation patterns of skin, therefore a highly confident 284 call cannot be made. Nonetheless, a pattern of cancer driver mutations in RF48 suggests it is 285
indeed not a stomach cell line (Fig 3a) . Past work based on gene expression suggested that RF48 286 is indeed not representative of stomach --instead, a lymphoid origin was proposed for RF48 (32). 287 288 Next, we sought to substantiate these findings using drug sensitivity data. In particular, two drugs 289 (dabrafenib and trametinib) that target mutant BRAF are approved for treating melanoma in the 290 clinic. These drugs are known to have poor efficacy in other cancer types bearing BRAF 291 mutations, such as in colon cancers (33) and therefore sensitivity to these drugs adds confidence 292 we are in fact looking at a melanoma cell line; (note that the converse does not necessarily hold 293 here: resistance does not imply it is not a melanoma). Therefore, we compared the IC50 of these 294 two drugs for all cell lines (Fig 3d) . As expected, many melanoma cell lines cluster at low values 295 of IC50 for the two drugs, meaning these cells are sensitive to the drugs. Among this cluster we 296 observed two out of five of our suspected cell lines (ES2 and MDST8) providing further supporting 297 evidence these are of skin, likely melanoma skin cancer origin. For the majority of the cancer types, we observed that one of the filtered subsets recovered a 387 higher number of significant (at FDR<= 25%) associations of CFE with drug sensitivity or 388 resistance, than were recovered using all cell lines ( Fig S7) . For instance, for glioblastoma, using 389 the 'golden set' cell lines we found 23 new associations, which were not recovered from the entire 390 cell line panel nor from the random-subset controls (Fig 4b) . For example, this recovers the 391 positive association of CDKN2A loss with camptothecin sensitivity (Fig 4c) , which was previously 392 reported in an independent analysis of the NCI-60 cell line panel screening data (41). Similarly, 393 for pancreatic adenocarcinoma, benefits were observed by focusing on cell lines that resemble 394 the corresponding cancer type better: using only the 'golden set' plus 'silver set' cell lines, 10 new 395 significant associations were found (Fig 4b) . For instance, we detected that SMAD4-mutant cell 396 lines are more resistant to piperlongumine, a natural product claimed to have antitumor properties 397
Fig. 4. Drug sensitivity association testing using high-confidence sets of cell lines. (a) Drug sensitivity (IC50) to dabrafenib in all CRAD cell lines (left) and all CRAD cell lines except MDST8, which is suspected of being skin cancer (right). Two groups are compared: cell lines with BRAF mutation and without (wild-type). ANOVA FDR for this association (dabrafenib and BRAF mutation) shown in blue for both datasets. Horizontal line is shown at 0, because score <0 implies sensitivity to the drug. (b) Number of significant associations between Cancer Functional Events (CFEs) and drugs detected in the ANOVA test for all cell lines (ALL), cell lines in the golden set (G), cell lines in the golden plus silver set (G&S), random subset of cell lines that match the number of cell lines in the golden set (r_G) and in the golden plus silver set (r_G&S)
. For the random subsets, the number of significant associations is calculated 10 times (with different random selection) and the median of the 10 runs is shown. P-values for a sign test (one-tailed, alternative = "less") between the number of associations in the G/G&S versus the number of associations in r_G/r_G&S are shown. See Fig S7 for remaining cancer types. (c) Differential sensitivity of drugs were analysed by ANOVA for all brain cancer cell lines (left) and the brain cancer cell lines in the golden set only (right). Each point is an association between the sensitivity of a drug and a genetic feature (CFE). (d) Differential sensitivity of drugs were analysed by ANOVA for all pancreatic (PAAD) cell lines (left) and PAAD cell lines in the golden and silver set only (right). Each point is an association between the sensitivity of a drug and a genetic feature (CFE).
two drug screens and two genetic screens suggests high strength of combined evidence 455 (p=0.00094, Fisher's method of combining p-values) linking the loss at 1p32.3 (chr1: 51169045-456 51472178) with sensitivity to pharmacological or genetic EGFR inhibition in brain cells, suggesting 457 a strong candidate for follow-up work. 458
459
In summary, the presence of cell lines with dubious or incorrect labels of tissue identity may 460 strongly impact association studies of drug or CRISPR screening data in two different ways. First, 461 the presence of mislabelled cell lines can cause the appearance of spurious associations that do 462 not reflect the biology of the cancer type of interest. Second, the presence of mislabelled or 463 divergent cell lines can prevent the recovery of true associations. 464
Fig. 5. Analysis of genetic screening data using high-confidence cell lines. (a) Number of significant associations between Cancer Functional Events (CFEs) and gene dependencies (in CRISPR knockout screens) detected in the ANOVA test for all cell lines (ALL), cell lines in the golden set (G), cell lines in the golden and silver set (G&S), random subset of cell lines that match the number of cell lines in the golden set (r_G) and in the golden and silver set (r_G&S).
For the random subsets, the number of significant associations is calculated 10 times and median. P-value for a sign test (one-tailed) between the associations in the G/G&S and the associations in the 10 runs of r_G/r_G&S are shown. See Fig S8 for remaining cancer types. (b 
) Fitness effect (fold change) for MED8 k.o. in all OV cell lines (left) and all OV cell lines except SW626, which is suspected of originating from CRAD (right). Two groups are compared: cell lines with copy number gain in a region containing ASXL1 (gain_cnaOV72), and without (wild-type). ANOVA FDR for this association (MED8 k.o. and gain_cnaOV72) is shown in blue for both datasets. (c) Fitness effect (fold change) for TUBB4B k.o. in all CRAD cell lines (left) and all CRAD cell lines except MDST8
, which is suspected to originate from skin (right). Two groups are compared: cell lines with copy number gain in region containing STK4 (gain_cnaCOREAD32) and without (wild-type). ANOVA FDR for this association (TUBB4B k.o. and gain_cnaCOREAD32) shown in blue for both datasets. (d) Differential dependency biomarkers were analysed by ANOVA for all ovarian cancer (OV) cell lines (left) and OV cell lines in the golden and silver set only (right). Each point is an association between the fitness effect of a gene and a genetic feature (CFE).
in the CL dataset. In particular, we calculated the Area Under the Receiver Operating 616
Characteristic curves (AUC) and the Area Under the Precision Recall curve (AUPRC) for each 617 cancer type vs the rest (all the rest of cancer types combined). 618 619 FDR Score. For each cell line, we calculated an FDR score of belonging to a particular cancer 620 type. For this, we divided the TCGA data into two datasets (training and testing) of the same size 621 keeping the cancer type proportions. For each cancer type, we trained classifiers in the TCGA 622 training dataset and we introduced the cell lines one by one with the testing data and calculated 623 the precision recall (PR) curve (TCGA testing + 1CL). We set the cell line FDR score for that 624 specific cancer type as (1 -precision) at the threshold where the cell line is situated in the PR 625 curve. Overall, for every cell line we obtained 17 FDR scores, 1 for each possible cancer type. 626
We repeated this procedure 5 times and calculated the median FDR for every case to get more 627 robust values. In addition, when training for 1 cancer type (label = 1) versus the rest of cancer 628 types combined (label = 0) we made some exceptions and removed those cancer types which 629 are similar and therefore the classifier is not good at separating them (e.g. when we calculated 630 
